Asciminib, ASCIMINIB HYDROCHLORIDE
CABL001I12202
Phase 2 small_molecule active
Quick answer
Asciminib, ASCIMINIB HYDROCHLORIDE for Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active